Society of Hematologic Oncology

Society of Hematologic Oncology Become a member of SOHO today for free! Register for SBBC at soho.click/SBBC on November 20 SOHO is led by a Board of Directors with six voting members.

SOHO is the only international society for clinicians, scientists & related professionals who specialize in the research & treatment of hematologic malignancies. The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

FDA approves blenrep combo in relapsed or refractory MM
10/23/2025

FDA approves blenrep combo in relapsed or refractory MM

The US Food and Drug Administration (FDA) has approved belantamab mafodotin (blenrep) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least two prior lines of therapy, including a protea...

ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS
10/21/2025

ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS

The phase 3 VERONA trial did not meet its primary endpoint of overall survival in patients with high-risk myelodysplastic syndromes, according to results presented at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025). The study, presented by Guillermo Garcia-Manero, MD...

10/20/2025

Register today for SOHO's virtual meeting, SOHO Breakthroughs in Blood Cancers (SBBC) at http://soho.click/SBBC. Dr. Sagar Lonial gives a sneak peak at what attendees can expect. SBBC will be held on Nov. 20 & is free 4 SOHO members; $50 for non-SOHO members. Join SOHO for free at soho.click/join.

Muhammad Bilal Abid, MD, MS, on protecting patients with blood cancers from COVID-19
10/11/2025

Muhammad Bilal Abid, MD, MS, on protecting patients with blood cancers from COVID-19

Dr. Abid, a clinician-scientist at the University of Texas Health Science Center in Houston, outlined the heightened risks COVID-19 poses for immunocompromised patients…

Early-phase CLL trial shows bexobrutideg well tolerated
10/09/2025

Early-phase CLL trial shows bexobrutideg well tolerated

Updated results from an early-phase chronic lymphocytic leukemia trial of heavily pretreated patients showed that once-daily dosing of the Bruton’s tyrosine kinase (BTK) inhibitor bexobrutideg was well-tolerated. The data were presented in an oral abstract session at the Thirteenth Annual Meeting ...

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia
10/03/2025

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia

By: Emily Hayes Attendees of SOHO 2025 got a closer look at positive early safety and efficacy data for the novel Bruton’s tyrosine kinase (BTK)-targeted drug bexobrutideg in heavily pretreated Waldenström macroglobulinemia (WM). Orally available bexobrutideg (bexdeg for short) is designed to eli...

SOHO 2026 exhibit & sponsorship opportunities are open! Connect with 3,000+ HemOnc professionals, maximize visibility, a...
10/02/2025

SOHO 2026 exhibit & sponsorship opportunities are open! Connect with 3,000+ HemOnc professionals, maximize visibility, and build lasting connections. Space is limited and first-come, first-served—secure your spot today at soho.click/sponsors

Radiation from medical imaging increases risk of blood cancers in children
10/02/2025

Radiation from medical imaging increases risk of blood cancers in children

A retrospective study of North American children and adolescents published in the New England Journal of Medicine suggests an association between exposure to radiation from medical imaging and a small but significantly increased risk of hematologic cancer. The study followed a retrospective cohort o...

Now you can literally wear your support for SOHO on your sleeve! Stop by the SOHO Boutique near the skybridge to learn h...
09/04/2025

Now you can literally wear your support for SOHO on your sleeve!

Stop by the SOHO Boutique near the skybridge to learn how you can support SOHO’s mission & get branded SOHO merch.

Help us name our new SOHO mascot by voting in our poll!
08/27/2025

Help us name our new SOHO mascot by voting in our poll!

“You made the possible impossible.” Attendee comment at Brandon Imber’s () presentation on split-course radiotherapy pri...
06/18/2025

“You made the possible impossible.” Attendee comment at Brandon Imber’s () presentation on split-course radiotherapy prior to -T in R/R BCL

Rise and shine . Never gets old!
06/18/2025

Rise and shine . Never gets old!

Address

The Woodlands, TX
77393

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Website

http://sohoinsider.com/, http://soho.click/SBBC

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Society of Hematologic Oncology:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About the Society

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. “Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Sixth Annual Meeting is scheduled for September 12-15, 2018 at the Hilton Americas-Houston in Houston, Texas. The society expects approximately 1,200 physicians and related professionals to attend the 3.5-day event. (go to soho2018.org for more information, abstract submissions and registration).